Edition:
United States

MannKind Corp (MNKD.OQ)

MNKD.OQ on NASDAQ Stock Exchange Global Market

0.53USD
17 Feb 2017
Change (% chg)

$-0.01 (-1.96%)
Prev Close
$0.54
Open
$0.55
Day's High
$0.55
Day's Low
$0.52
Volume
613,774
Avg. Vol
1,062,761
52-wk High
$2.24
52-wk Low
$0.41

MNKD.OQ

Chart for MNKD.OQ

About

MannKind Corporation is a biopharmaceutical company. The Company is focused on the discovery and development of therapeutic products for diseases, such as diabetes. Its product candidate is AFREZZA, which is an inhaled insulin used to control high blood sugar in adults with type I and type II diabetes and helps in glycemic... (more)

Overall

Beta: 3.25
Market Cap(Mil.): $251.76
Shares Outstanding(Mil.): 478.64
Dividend: --
Yield (%): --

Financials

  MNKD.OQ Industry Sector
P/E (TTM): -- 47.80 29.39
EPS (TTM): -0.52 -- --
ROI: -40,821.27 -4.08 13.06
ROE: -- 4.84 14.19

BRIEF-MannKind launches new titration pack and field force expansion to accelerate Afrezza growth

* MannKind announces launch of new titration pack and field force expansion to accelerate Afrezza growth

Feb 01 2017

BRIEF-Mannkind entered into agreement of purchase and sale and joint Escrow Instructions with Rexford Industrial Realty - SEC Filing

* Mannkind - On Jan 6, 2017, co entered into agreement of purchase and sale and joint Escrow Instructions with Rexford Industrial Realty - SEC Filing

Jan 12 2017

BRIEF-MannKind says receives $30.6 million from Sanofi

* MannKind receives $30.6 million from Sanofi Source text for Eikon: Further company coverage:

Jan 09 2017

BRIEF-Mannkind and Sanofi reach agreement on Afrezza

* Sanofi will purchase $10.2 million worth of insulin from Mannkind in early December as part of its preexisting commitment

Nov 09 2016

BRIEF-Mannkind - Enters into settlement agreement with Sanofi-Aventis

* Mannkind Corp - co, other entities entered into a settlement agreement with Sanofi-Aventis U.S. LLC - SEC filing

Nov 09 2016

BRIEF-Securities Class Action Against MannKind Dismissed

* U.S. District court for central district of California has dismissed class action that was pending against Mannkind and two of executives

Aug 25 2016

BRIEF-Mannkind's cco Michael Castagna reports open market purchase of 25,000 shares for $0.94 per share

* Mannkind's cco Michael Castagna reports open market purchase of 25,000 shares of co's common stock on august 23 for $0.94per share Source text - http://bit.ly/2bmQuTg Further company coverage:

Aug 24 2016

More From Around the Web

Competitors

  Price Chg
Novo Nordisk A/S (NOVOb.CO) kr.247.00 +0.60
Pfizer Inc. (PFE.N) $33.62 0.00
Sanofi SA (SASY.PA) €81.49 --
Eli Lilly and Co (LLY.N) $80.39 +0.35
Nektar Therapeutics (NKTR.OQ) $13.10 +0.12
Albireo Pharma Inc (ALBO.OQ) $23.00 +0.41

Earnings vs. Estimates